Detalles de la búsqueda
1.
A phase I trial to determine safety and pharmacokinetics of ASLAN002, an oral MET superfamily kinase inhibitor, in patients with advanced or metastatic solid cancers.
Invest New Drugs
; 36(5): 886-894, 2018 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-29766337
2.
Lower trial participation by culturally and linguistically diverse (CALD) cancer patients is largely due to language barriers.
Asia Pac J Clin Oncol
; 14(1): 52-60, 2018 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-29083094
Resultados
1 -
2
de 2
1
Próxima >
>>